Advertisement

Topics

Genexine Seals I-O Licensing Deal With I-Mab, Builds Momentum

01:16 EST 26 Dec 2017 | SCRIP

Genexine has reached a critical point in developing its immuno-oncology pipeline, firming up a $548m-plus licensing out pact for an...

      

Related Stories

 

Original Article: Genexine Seals I-O Licensing Deal With I-Mab, Builds Momentum

NEXT ARTICLE

More From BioPortfolio on "Genexine Seals I-O Licensing Deal With I-Mab, Builds Momentum"

Quick Search
Advertisement
 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...